168 related articles for article (PubMed ID: 12808885)
1. MK-767. Kyorin/Banyu/Merck.
Calkin AC; Thomas MC; Cooper ME
Curr Opin Investig Drugs; 2003 Apr; 4(4):444-8. PubMed ID: 12808885
[TBL] [Abstract][Full Text] [Related]
2. Exenatide. Amylin/Eli Lilly.
Giannoukakis N
Curr Opin Investig Drugs; 2003 Apr; 4(4):459-65. PubMed ID: 12808888
[TBL] [Abstract][Full Text] [Related]
3. Insulin detemir. Novo Nordisk.
Barlocco D
Curr Opin Investig Drugs; 2003 Apr; 4(4):449-54. PubMed ID: 12808886
[TBL] [Abstract][Full Text] [Related]
4. [Clinical efficacy of Pioglitazone (AD-4833)].
Kaneko T; Baba S
Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
[No Abstract] [Full Text] [Related]
5. Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist.
Drew BG; Calkin AC
Curr Opin Investig Drugs; 2007 Apr; 8(4):324-30. PubMed ID: 17458183
[TBL] [Abstract][Full Text] [Related]
6. [Against insulin resistance. Insulin sensitizers].
Verspohl EJ; Weiland F
Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
[No Abstract] [Full Text] [Related]
7. [KRP-297, MCC-555].
Yamanouchi T
Nihon Rinsho; 2001 Nov; 59(11):2200-6. PubMed ID: 11712408
[TBL] [Abstract][Full Text] [Related]
8. Insulin glulisine. Aventis Pharma.
Barlocco D
Curr Opin Investig Drugs; 2003 Oct; 4(10):1240-4. PubMed ID: 14649217
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.
Schimke K; Davis TM
Curr Opin Investig Drugs; 2007 Apr; 8(4):338-44. PubMed ID: 17458185
[TBL] [Abstract][Full Text] [Related]
10. [Glitazones--a new class of drugs in treatment of type 2 diabetes].
Kleinwechter H
Dtsch Med Wochenschr; 2002 Feb; 127(8):400-1. PubMed ID: 11859452
[No Abstract] [Full Text] [Related]
11. Thiazolidinediones in the treatment of type 2 diabetes: a clinician's perspective.
Buse JB
Am J Manag Care; 2000 Aug; 6(13 Suppl):S710-7. PubMed ID: 11183423
[No Abstract] [Full Text] [Related]
12. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
13. SomatoKine. Insmed.
Norman P
Curr Opin Investig Drugs; 2003 Apr; 4(4):466-71. PubMed ID: 12808889
[TBL] [Abstract][Full Text] [Related]
14. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
15. Tetomilast.
O'Mahony S
IDrugs; 2005 Jun; 8(6):502-7. PubMed ID: 15906198
[TBL] [Abstract][Full Text] [Related]
16. CLX-0901 (Calyx Therapeutics).
Barlocco D
Curr Opin Investig Drugs; 2001 May; 2(5):650-3. PubMed ID: 11569941
[TBL] [Abstract][Full Text] [Related]
17. [New insulin sensitizers].
Einecke D
MMW Fortschr Med; 1999 Oct; 141(42):6. PubMed ID: 10912094
[No Abstract] [Full Text] [Related]
18. Muraglitazar (Bristol-Myers Squibb/Merck).
Barlocco D
Curr Opin Investig Drugs; 2005 Apr; 6(4):427-34. PubMed ID: 15898350
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone (Actos).
Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
[No Abstract] [Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Herman GA; Stein PP; Thornberry NA; Wagner JA
Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
